transforming-growth-factor-alpha and Weight-Gain

transforming-growth-factor-alpha has been researched along with Weight-Gain* in 4 studies

Other Studies

4 other study(ies) available for transforming-growth-factor-alpha and Weight-Gain

ArticleYear
Chemoprevention of preneoplastic liver foci development by dietary mushroom Agaricus blazei Murrill in the rat.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2003, Volume: 41, Issue:11

    The chemopreventive potential of an Agaricus blazei (Ab) Murrill mushroom meal was investigated in a medium-term rat liver carcinogenesis assay. Male Wistar rats initiated for hepatocarcinogenesis with diethylnitrosamine (DEN, 200 mg/kg i.p.) were fed during a 6-week period with the dry powdered mushroom strains Ab 29 or 26, each one with opened (OB) or closed basidiocarp (CB), mixed at 10% level in a basal diet. All experimental animals and controls were subjected to partial hepatectomy at week 3 and killed at week 8. Chemopreventive activity of the mushroom meal was observed for the Ab 29 (OB and CB) and Ab 26 (CB) strains in terms of the number of putative preneoplastic altered foci of hepatocytes which express either the enzyme glutathione S-transferase, placental form (GST-P+) or the transforming growth factor-alpha, and for the Ab 29 (OB) and Ab 26 (CB) strains on the size of GST-P+ foci. This was associated with inhibition of foci cell proliferation in the animals fed the Ab 29 (OB) and Ab 26 (CB) strains. The results suggest that the protective influence of the Ab meal against the DEN potential for rat liver carcinogenicity depends on both the strain and period of mushroom harvest.

    Topics: Agaricus; Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Diet; Diethylnitrosamine; Eating; Glutathione Peroxidase; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Male; Organ Size; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Transforming Growth Factor alpha; Weight Gain

2003
Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model.
    American journal of physiology. Gastrointestinal and liver physiology, 2002, Volume: 282, Issue:1

    Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease of prematurely born infants. Maternal milk plays an important protective role against NEC development and is the major source of epidermal growth factor (EGF) for neonates. The aim of this study was to examine the effect of orally administered EGF on the incidence of NEC in a neonatal rat model. Newborn rats were artificially fed either with growth factor-free rat milk substitute (RMS) or RMS supplemented with 500 ng/ml of EGF (RMS+EGF). Experimental NEC was induced by exposure to asphyxia and cold stress. Development of NEC was evaluated by gross and histological scoring of damage in the ileum. Ileal EGF receptor (EGF-R), EGF, and transforming growth factor-alpha mRNA expression was assessed by RT competitive-PCR, and the EGF-R was localized by immunohistochemistry. EGF supplementation of formula reduced the incidence and severity of NEC in rats (13/16 RMS vs. 4/13 RMS+EGF). Ileal EGF-R mRNA expression was markedly increased in the RMS group compared with RMS+EGF. Enhanced EGF-R expression in the RMS group was localized predominantly in the epithelial cells of injured ileum. These data suggest a new potential therapeutic approach for the prevention and treatment of NEC.

    Topics: Animals; Animals, Newborn; Disease Models, Animal; Enterocolitis, Necrotizing; Epidermal Growth Factor; ErbB Receptors; Gene Expression; Ileum; Incidence; Milk; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transforming Growth Factor alpha; Weight Gain

2002
Glucose-regulated insulin expression in diabetic rats.
    Human gene therapy, 2001, Jan-20, Volume: 12, Issue:2

    Retroviral vectors encoding glucose-responsive promoters driving furin expression may provide an amplified, glucose-regulated secretion of insulin. We constructed LhI*TFSN virus to encode a glucose-regulatable transforming growth factor alpha promoter controlling furin expression with a viral LTR promoter driving constitutive expression of furin-cleavable human proinsulin. Autologous BB rat vascular smooth muscle cells transduced with LhI*TFSN virus and cultured in 1.7 and 16.7 mM glucose secreted 50.7 +/- 3.2 and 136.0 +/- 11.0 microU (mean +/- SD) of insulin per 10(6) cells per day, respectively. After the onset of diabetes spontaneously diabetic congenic DR lyp/lyp BB rats received stomach implants containing 2 x 10(6) LhI*TFSN-transduced primary rat vascular smooth muscle cells. In eight treated rats there was a major reduction in insulin requirement to as low as 25% of pretreatment level for up to 3 months and one rat became insulin free without hypoglycemia. Intraperitoneal glucose tolerance tests (IPGTTs) in diabetic rats receiving control implants did not show the characteristic decline in blood glucose of normal rats after glucose administration. In contrast, diabetic rats receiving LhI*TFSN-transduced cells showed significant clearances of blood glucose. These data suggest clinically significant levels of glucose-regulated insulin delivery from implanted vascular smooth muscle cells transduced with LhI*TFSN vector.

    Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 1; Erythropoietin; Furin; Glucose; Glucose Tolerance Test; Humans; Insulin; Male; Muscle, Smooth, Vascular; Promoter Regions, Genetic; Rats; Rats, Inbred BB; RNA, Messenger; Subtilisins; Transduction, Genetic; Transforming Growth Factor alpha; Weight Gain

2001
Weight gain does not preclude increased ubiquitin conjugation in skeletal muscle: an exploratory study in tumor-bearing mice.
    Annals of nutrition & metabolism, 2001, Volume: 45, Issue:3

    At least 13 studies have shown that the ubiquitin-proteasome system mediates muscle wasting in weight-losing cancer subjects. We hypothesized that cancer itself may activate the ubiquitin-proteasome system, regardless of weight loss.. We utilized hybrid mice obtained by crossing Mouse Mammary Tumor Virus-Transforming Growth Factor-alpha (TGF-alpha) mice with the Lep(ob) strain. Five hybrid MMTV-TGF-alpha heterozygous Lep(+)Lep(ob) female mice with mammary tumors were used; 4 nontransgenic heterozygous Lep(+)Lep(ob) female mice served as controls. Ubiquitin conjugates were quantitated from hamstring and paraspinal muscles by Western blotting. Myocyte apoptosis was determined by a modified TUNEL assay.. All mice gained weight, even after tumor development. Higher concentrations of muscle ubiquitin conjugates were seen in the 5 tumor-bearing, TGF-alpha transgenic mice as compared with the 4 non-tumor-bearing mice: median (range) in arbitrary densitometric units: 0.67 (0.22-4.59) versus 0.18 (0.08-0.44) in hamstring muscle and 0.56 (0.23-20.15) versus 0.18 (0.08-0.25) in paraspinal muscle (p = 0.04 and p = 0.04, respectively; Mann-Whitney U test). Apoptosis was not seen in any muscle sample studied.. Ubiquitin conjugates are increased in the skeletal muscle of tumor-bearing mice in the absence of weight loss. Such activation is not seen in the skeletal muscle on non-tumor-bearing mice. Further studies might focus of whether this observation is relevant to cancer-associated wasting of lean tissue.

    Topics: Adenocarcinoma; Animals; Apoptosis; Cachexia; Cysteine Endopeptidases; Disease Models, Animal; Female; Immunoblotting; In Situ Nick-End Labeling; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Multienzyme Complexes; Muscle Proteins; Muscle, Skeletal; Proteasome Endopeptidase Complex; Transforming Growth Factor alpha; Ubiquitins; Weight Gain

2001